NEWAMSTERDAM PHARMA CO NV (NAMS)

NL00150012L7 - Common Stock

20.01  -3.67 (-15.5%)

After market: 20 -0.01 (-0.05%)

Full estimates are only available for subscribed users, you can see which data is available below.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031
Revenue
YoY % growth
97.5M13.254M
-86.41%
EBITDA
YoY % growth
-126.66K-1.352M
-967.65%		-3.867M
-185.96%		-238.852M
-6,076.67%
EBIT
YoY % growth
-127.66K-1.366M
-970.25%		-3.939M
-188.30%		-195.241M
-4,856.62%
Operating Margin
N/AN/A-4.04%-1,473.07%
EPS
YoY % growth
N/AN/AN/A-2.21
-1,306.89%

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q4 / 23 Q1 / 24 Q2 / 24 Q3 / 24 Q4 / 24 Q1 / 25 Q2 / 25 Q3 / 25 Q4 / 25 Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26
EPS
Q2Q % growth
Revenue
Q2Q % growth
EBITDA
Q2Q % growth
EBIT
Q2Q % growth

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q3 2023
Q2Q % growth		 -0.55
4.59%		-0.50-0.06-11.52%
Q2 2022
Q2Q % growth
Q1 2022
Q2Q % growth
Q4 2021
Q2Q % growth
Q3 2021
Q2Q % growth
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q3 2023
Q2Q % growth		 2.977M 2.291M686.42K29.96%
Q2 2023
Q2Q % growth		 9.562M 2.794M6.768M242.23%
Q4 2022
Q2Q % growth		 97.5M 3.561M93.939M2,637.99%
Q3 2022
Q2Q % growth		 1.687M-1.687M-100.00%
Q2 2022
Q2Q % growth
Q1 2022
Q2Q % growth
Q4 2021
Q2Q % growth
Q3 2021
Q2Q % growth
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPS0% 0% 0% -16.39%
Revenue0% 0% 0% 86.41%